From Aiolos to Kailera: Who Captures the Value in a China-to-Global NewCo? Jul 26 Written by Yihang Chen Yihang Chen Previous Previous BINSA and the WuXi AppTec Case: Two Distinct Tracks in U.S. Biotech National Security Policy Next Next Clinical Going Global: Why Australia and Europe Matter More for Chinese Biotech
From Aiolos to Kailera: Who Captures the Value in a China-to-Global NewCo? Jul 26 Written by Yihang Chen Yihang Chen